OptimizeRx (OPRX) Return on Capital Employed (2011 - 2026)

OptimizeRx (OPRX) has 16 years of Return on Capital Employed data on file, last reported at 8.79% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 1592.0% year-over-year to 8.79%; the trailing twelve-month figure through Mar 2026 stood at 8.79% (up 1592.0% YoY), and the FY2025 full-year result was 7.65%, up 1629.0% from the prior year.
• Return on Capital Employed grew to 8.79% in Q1 2026, from 7.68% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 8.79% in Q1 2026 to a low of 19.42% in Q4 2023.
• A 5-year average of 7.66% and a median of 9.17% in 2024 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed slumped 1034 bps in 2023 and surged 2275 bps in 2025, its largest moves.
• Tracing OPRX's Return on Capital Employed over 5 years: stood at 9.69% in 2022, then sank by 100 bps to 19.42% in 2023, then soared by 53 bps to 9.17% in 2024, then jumped by 184 bps to 7.68% in 2025, then grew by 14 bps to 8.79% in 2026.
• Business Quant data shows OPRX's Return on Capital Employed at 8.79% in Q1 2026, 7.68% in Q4 2025, and 4.47% in Q3 2025.